drugset / Trial / NCT06944444
A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study was an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSS59 as a single agent in patients with advanced malignancies.
Timeline
- Start
- 2025-04-27
- Primary completion
- 2027-03-01
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SSS59 | Monoclonal antibody | — | Intravenous |